Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01132495 · ClinicalTrials.gov registry record · NA
FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 1,170
- Enrollment target
NCT01132495 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 1,170 participants.
The verdict
NCT01132495, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,170 participants
- Enrollment target
Study Summary
The overall purpose of the FAME II trial is to compare the clinical outcomes, safety and cost-effectiveness of FFR-guided PCI plus optimal medical treatment (OMT) versus OMT alone in patients with stable coronary artery disease.
Interventions
- OTHER Standard of care
- OTHER OMT
- OTHER Stenting plus OMT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,170 participants |
| Start Date | 2010-05 |
| Est. Completion | 2015-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01132495
The ClinicalTrials.gov registry entry for NCT01132495 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Standard of care is the first listed.
NCT01132495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01132495 about?
NCT01132495 is a clinical study titled "FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT". The overall purpose of the FAME II trial is to compare the clinical outcomes, safety and cost-effectiveness of FFR-guided PCI plus optimal medical treatment (OMT) versus OMT alone in patients with stable coronary artery disease.
What is the current status of trial NCT01132495?
This trial is currently completed. It is a NA study. The enrollment target is 1,170 participants. The study started on 2010-05. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01132495?
The interventions under investigation include: Standard of care (OTHER), OMT (OTHER), Stenting plus OMT (OTHER).
Who is sponsoring clinical trial NCT01132495?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.